All articles
Eli Lilly Just Went Direct-to-Employer With GLP-1s, Here's Why Middlemen Should Be Worried
Eli Lilly bypassed the insurance industry. Eli Lilly bypassed the insurance industry. Eli Lilly bypassed the insurance industry.
The math explains why this model exists. At $449/month — roughly $5,400/year per employee — an employer with 100 participants is looking at $540,000 annually. That's real money, but it's predictable money. And it's a fraction of the downstream costs of untreated obesity: diabetes management, cardiovascular events, orthopedic procedures, disability claims.
The distribution disruption. Lilly just created a new channel that cuts out PBMs and traditional insurance formularies. If this model works — and the demand signals suggest it will — expect Novo Nordisk to follow within months. The employer benefits ecosystem is about to look very different.
The cost visibility play. The arrangement doesn't involve rebates, which is the quiet revolution here. Rebates are how PBMs extract value and obscure true drug costs. A transparent net price gives employers something they've never had: the ability to model the actual cost of covering obesity treatment and make an informed decision.
The ripple effect. If you sell anything adjacent to employer health benefits — digital therapeutics, chronic care management, wellness platforms, benefits administration — this is your market being reshaped in real time. When pharma goes direct-to-employer, every intermediary has to justify its existence. The companies that can prove ROI on top of GLP-1 treatment (behavioral support, outcomes measurement, cost analytics) will thrive. The ones selling standalone weight management programs just lost their pricing power.
.webp){kind=logo}